Biogen/Eisai Alzheimer Drug Wins Favorable Vote from FDA Advisory Committee
- Posted by ISPE Boston
- On June 15, 2023
Biogen and partner Eisai have announced that the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease (AD). Additionally, the committee members confirmed the overall benefit-risk profile of Leqembi, the […]
Read More